Skip to main content

Table 4 Mortalitya by cg05575921 percent methylation for all lung cancer cases and by histotype

From: AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality

  All lung cancer casesb Adenocarcinoma Squamous cell carcinoma Small cell
cg05575921
methylation %
Deaths Total HR (95% CI) Deaths Total HR (95% CI) Deaths Total HR (95% CI) Deaths Total HR (95% CI)
Lung cancer-specific mortality
Continuous 10% decrease 313 372 1.08 (0.98, 1.19) 117 148 1.21 (1.03, 1.43) 94 115 0.98 (0.82, 1.17) 77 81 1.20 (0.93, 1.54)
Q1 (highest; hyper-methylated) 59 74 Ref 23 31 Ref 15 19 Ref 16 19 Ref
Q2 61 74 0.93 (0.64, 1.36) 26 35 1.11 (0.58, 2.11) 20 23 1.02 (0.48, 2.14) 12 13 1.01 (0.37, 2.70)
Q3 63 75 1.12 (0.75, 1.67) 21 28 1.09 (0.54, 2.19) 12 17 0.89 (0.39, 2.03) 24 24 1.79 (0.79, 4.02)
Q4 65 74 1.13 (0.75, 1.71) 23 27 1.97 (0.95, 4.10) 23 27 0.86 (0.39, 1.92) 14 14 1.01 (0.35, 2.88)
Q5 (lowest; hypo-methylated) 65 75 1.46 (0.95, 2.22) 24 27 2.32 (1.12, 4.82) 24 29 1.07 (0.49, 2.36) 11 11 3.68 (1.32, 10.25)
  P-trend 0.05 P-trend 0.01 P-trend 1.00 P-trend 0.04
All-cause mortality
Continuous 10% decrease 357 372 1.07 (0.97, 1.17) 137 148 1.21 (1.03, 1.41) 113 115 0.97 (0.82, 1.14) 80 81 1.14 (0.89, 1.47)
Q1 (highest; hyper-methylated) 73 74 Ref 30 31 Ref 19 19 Ref 19 19 Ref
Q2 69 74 0.87 (0.61, 1.24) 31 35 1.05 (0.58, 1.89) 23 23 1.10 (0.56, 2.20) 12 13 0.82 (0.31, 2.18)
Q3 71 75 1.07 (0.74, 1.56) 24 28 1.08 (0.56, 2.11) 17 17 1.11 (0.53, 2.31) 24 24 1.45 (0.66, 3.17)
Q4 70 74 1.01 (0.68, 1.49) 25 27 1.65 (0.83, 3.29) 26 27 0.78 (0.36, 1.66) 14 14 0.83 (0.30, 2.28)
Q5 (lowest; hypo-methylated) 74 75 1.42 (0.96, 2.10) 27 27 2.37 (1.20, 4.71) 28 29 1.04 (0.50, 2.17) 11 11 2.95 (1.09, 7.96)
  P-trend 0.06 P-trend 0.01 P-trend 0.76 P-trend 0.09
  1. Abbreviations: CI confidence Interval, NSCLC non-small cell lung cancer, NSCLC, NOS non-small cell lung cancer, not otherwise specified, HR hazard ratio
  2. aCox proportional hazards model results adjusted for age at blood draw, sex, years between blood draw and lung cancer diagnosis, and years since quit smoking at blood draw. All models include early, late, or unknown stage as a strata variable
  3. b “All lung cancer cases” includes adenocarcinoma, squamous cell carcinoma, and small cell cases as well as not otherwise specified non-small cell lung cancer (NSCLC, NOS; n = 16) and unknown/no pathology (n = 12)